Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma | Zendy

MaríaVictoria Mateos | Zendy; Meletios Α. Dimopoulos | Zendy; Michèle Cavo | Zendy; Kenshi Suzuki | Zendy; Andrzej Jakubowiak | Zendy; Stefan Knop | Zendy; Chantal Doyen | Zendy; Paulo Lúcio | Zendy; Zsolt Nagy | Zendy; Polina Kaplan | Zendy; Luděk Pour | Zendy; Mark Cook | Zendy; Sebastian Grosicki | Zendy; Andre H Crepaldi | Zendy; Anna Marina Liberati | Zendy; Philip Campbell | Zendy; Tatiana Shelekhova | Zendy; SungSoo Yoon | Zendy; Genadi Iosava | Zendy; Tomoaki Fujisaki | Zendy; Mamta Garg | Zendy; Christopher Chiu | Zendy; Jianping Wang | Zendy; Robin Carson | Zendy; Wendy Crist | Zendy; William Deraedt | Zendy; Huong Nguyen | Zendy; Ming Qi | Zendy; Jesús F. San Miguel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Author(s) -

MaríaVictoria Mateos,

Meletios Α. Dimopoulos,

Michèle Cavo,

Kenshi Suzuki,

Andrzej Jakubowiak,

Stefan Knop,

Chantal Doyen,

Paulo Lúcio,

Zsolt Nagy,

Polina Kaplan,

Luděk Pour,

Mark Cook,

Sebastian Grosicki,

Andre H Crepaldi,

Anna Marina Liberati,

Philip Campbell,

Tatiana Shelekhova,

SungSoo Yoon,

Genadi Iosava,

Tomoaki Fujisaki,

Mamta Garg,

Christopher Chiu,

Jianping Wang,

Robin Carson,

Wendy Crist,

William Deraedt,

Huong Nguyen,

Ming Qi,

Jesús F. San Miguel

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1714678

Subject(s) - daratumumab , melphalan , bortezomib , medicine , multiple myeloma , prednisone , oncology , autologous stem cell transplantation , plasma cell myeloma , lenalidomide

The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or refractory multiple myeloma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research